The Burden of Major Adverse Cardiac Events and Antiplatelet Prevention in Patients with Coronary or Peripheral Arterial Disease-Reference-Cited by-同舟云学术

The Burden of Major Adverse Cardiac Events and Antiplatelet Prevention in Patients with Coronary or Peripheral Arterial Disease

Published:2016-03-03 Issue:2 Volume:34 Page:115-124
ISSN:1755-5914
Container-title:Cardiovascular Therapeutics
language:en
Short-container-title:Cardiovasc Ther

Author:

Khoury Hanane¹,Lavoie Louis¹,Welner Sharon¹,Folkerts Kerstin²

Affiliation:

1. LASER Analytica; Montreal QC Canada

2. Bayer Pharma AG; Wuppertal Germany

Funder

Bayer HealthCare

Publisher

Wiley

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine

Reference80 articles.

1. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology;Montalescot;Eur Heart J,2013

2. Prevalence of peripheral arterial disease - results of the Heinz Nixdorf recall study;Kroger;Eur J Epidemiol,2006

3. Peripheral arterial disease: a literature review;Abdulhannan;Br Med Bull,2012

4. Bayer Corporation Aspirin. Comprehensive prescribing information 2013 http://www.fda.gov/ohrms/dockets/ac/03/briefing/4012B1_03_Appd%201-Professional%20Labeling.pdf

5. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients;Antithrombotic Trialists' Collaboration;BMJ,2002

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recurrent cardiovascular and limb events in 294,428 patients with coronary or peripheral artery disease or ischemic stroke on antiplatelet monotherapy: The RESRISK cohort study;Atherosclerosis;2024-11

2. Caught Between Heart and Limbs: Navigating the Treatment of Patients With CAD and PAD in an Overwhelmed Healthcare System;Angiology;2023-09-25

3. Risk Factors for Major Adverse Cardiac Events Outcomes in Post Percutaneous Coronary Intervention during Index Admission;JULY 2023;2023-07-07

4. Long-term Effects of Nicorandil Combined with Dihydropyridine Calcium Channel Blockers on Cardiovascular Outcomes in Patients with Coronary Heart Disease: A Real-world Observational Study;Cardiovascular Innovations and Applications;2023

5. Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice—Insights From the CANHEART Study;Journal of the American Heart Association;2022-12-20